SEHK:9926Biotechs
Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances
Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology.
The company also secured clearance for AK150, a globally first in class trispecific antibody, to begin clinical trials in patients with advanced solid tumors.
These approvals move multiple assets in Akeso's pipeline into clinical and mid stage development.
For investors tracking Akeso (SEHK:9926), these clearances come with the stock...